Cryoglobulin Characterization
| Sera . | Cryoglobulin Type . | No Cryoglobulin . | Total . | ||
|---|---|---|---|---|---|
| II . | II-III-150 . | III . | |||
| HCV | |||||
| RF > 100 | 4 | 10 | 22 | 24 | 60 |
| RF < 100 | 0 | 2 | 6 | 51 | 59 |
| HBV | |||||
| RF > 100 | 0 | 0 | 2 | 9 | 11 |
| RA | |||||
| RF > 100 | 0 | 1 | 11 | 5 | 17 |
| Sera . | Cryoglobulin Type . | No Cryoglobulin . | Total . | ||
|---|---|---|---|---|---|
| II . | II-III-150 . | III . | |||
| HCV | |||||
| RF > 100 | 4 | 10 | 22 | 24 | 60 |
| RF < 100 | 0 | 2 | 6 | 51 | 59 |
| HBV | |||||
| RF > 100 | 0 | 0 | 2 | 9 | 11 |
| RA | |||||
| RF > 100 | 0 | 1 | 11 | 5 | 17 |
Abbreviations: RA, rhumatoid arthritis; RF, rheumatoid factor activity (IU/mL).
Type II-III is characterized by the presence of an IgM oligoclonal pattern associated with polyclonal Ig. This type of cryoglobulin can be considered as a transition between cryoglobulins type II and III.